| P50 | author | Ferdinando Nicoletti | Q84521195 |
| | Michele Milella | Q85747913 |
| | Agostino Tafuri | Q85907041 |
| | Joanna Dulińska-Litewka | Q89586697 |
| | Lucio Ildebrando Cocco | Q90630488 |
| | Zoya N. Demidenko | Q110375454 |
| | Linda S Steelman | Q114723345 |
| | Lyudmyla Drobot | Q115726591 |
| | Stephen L Abrams | Q123366731 |
| | William H Chappell | Q123366743 |
| | Nicole M. Davis | Q123366803 |
| | Renato Talamini | Q16122860 |
| | Saverio Candido | Q56806923 |
| | Giuseppe Montalto | Q56806930 |
| | Alberto M Martelli | Q56922777 |
| | Camilla Evangelisti | Q57233682 |
| | Piotr Laidler | Q60185163 |
| | Richard A. Franklin | Q68547480 |
| | Jörg Baesecke | Q69033710 |
| | Melchiorre Cervello | Q78711908 |
| | Massimo Libra | Q37842996 |
| | Sanja Mijatović | Q39272010 |
| | Danijela Maksimović-Ivanić | Q39272047 |
| | Jerry Polesel | Q46784421 |
| | Marco Donia | Q40146733 |
| | James A. McCubrey | Q42317570 |
| P2093 | author name string | Lin Sun | |
| | Kazuo Umezawa | |
| | Paolo Fagone | |
| | Francesca Chiarini | |
| | Grazia Malaponte | |
| | Maria C Mazzarino | |
| | Antonio B D'Assoro | |
| P2860 | cites work | Reversing the Warburg effect through stromal autophagy | Q84833715 |
| | A beta version of life: p110β takes center stage | Q24293200 |
| | Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas | Q24303940 |
| | Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity | Q24596766 |
| | Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton | Q24600408 |
| | Potential use of rapamycin in HIV infection | Q24606795 |
| | HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis | Q24611063 |
| | Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment | Q24611183 |
| | Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism | Q24611305 |
| | From growing to secreting: new roles for mTOR in aging cells. | Q54577655 |
| | mTOR as a multifunctional therapeutic target in HIV infection. | Q54586477 |
| | Autophagic tumor stroma: A biofuel for cancer growth | Q61771832 |
| | The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis | Q37711289 |
| | The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. | Q37732880 |
| | Rapamycin and quasi-programmed aging: four years later | Q37740901 |
| | Targeting autophagy to fight hematopoietic malignancies. | Q37779468 |
| | p53, ROS and senescence in the control of aging | Q37781655 |
| | The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox | Q37807243 |
| | Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal | Q37819818 |
| | Cell cycle arrest is not senescence | Q37836231 |
| | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. | Q37837732 |
| | Drug discovery approaches to target Wnt signaling in cancer stem cells | Q37840943 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers | Q37866945 |
| | mTOR signaling in protein homeostasis: less is more? | Q37873702 |
| | Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs | Q37948887 |
| | Lipocalin 2 in cancer: when good immunity goes bad. | Q37954908 |
| | Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). | Q37971448 |
| | AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications | Q37976243 |
| | Targeting Mnks for cancer therapy | Q37990881 |
| | Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies | Q38017727 |
| | BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review). | Q38031762 |
| | Progeria, rapamycin and normal aging: recent breakthrough | Q38573503 |
| | p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. | Q39237016 |
| | Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. | Q39257895 |
| | Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer | Q39266588 |
| | The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes | Q39301469 |
| | Molecular mechanisms of sorafenib action in liver cancer cells. | Q39313526 |
| | Therapeutic potential of nitric oxide-modified drugs in colon cancer cells | Q39313996 |
| | Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a | Q39328413 |
| | Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. | Q39344848 |
| | Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. | Q39345747 |
| | The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism | Q24611412 |
| | Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TOR-independent manner, by modulating housekeeping longevity assurance processes | Q24616983 |
| | Targeting mTOR for the treatment of AML. New agents and new directions | Q24617223 |
| | Targeted therapy for hepatocellular carcinoma: novel agents on the horizon | Q27002288 |
| | The physiology and pathophysiology of rapamycin resistance: implications for cancer | Q28478235 |
| | Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives | Q28750492 |
| | DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence | Q28972513 |
| | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 |
| | Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 |
| | Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells | Q33759701 |
| | Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis | Q33896755 |
| | The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. | Q34024558 |
| | mTOR favors senescence over quiescence in p53-arrested cells | Q34056457 |
| | Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). | Q34097445 |
| | microRNA-451: A conditional switch controlling glioma cell proliferation and migration. | Q34127211 |
| | Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia | Q34164289 |
| | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway | Q34173253 |
| | Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance | Q34175179 |
| | INPP4B: the new kid on the PI3K block | Q34177821 |
| | Xenohormetic, hormetic and cytostatic selective forces driving longevity at the ecosystemic level | Q34194276 |
| | P66SHC and Ageing: ROS and TOR? | Q34194303 |
| | Hormesis, cell death and aging | Q34217654 |
| | The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms | Q34244242 |
| | Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. | Q34260622 |
| | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance | Q34307356 |
| | PI3Kα inhibitors that inhibit metastasis | Q34416746 |
| | The p53 inducing drug dosage may determine quiescence or senescence | Q34424866 |
| | Why the disposable soma theory cannot explain why women live longer and why we age. | Q34554291 |
| | Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma | Q34682072 |
| | The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? | Q34781888 |
| | Normalizing a hyperactive mTOR initiates muscle growth during obesity | Q34852371 |
| | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging | Q34966603 |
| | Gerosuppressant metformin: less is more | Q35052060 |
| | Aquaglyceroporins serve as metabolic gateways in adiposity and insulin resistance control | Q35079321 |
| | Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. | Q35124582 |
| | New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis | Q36455205 |
| | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine | Q36556350 |
| | Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. | Q36625664 |
| | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex | Q36706340 |
| | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response | Q36862768 |
| | A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia | Q36926129 |
| | Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer | Q37030911 |
| | Effects of ectopic expression of NGAL on doxorubicin sensitivity | Q37031268 |
| | Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer | Q37031288 |
| | Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs | Q37192602 |
| | The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy | Q37192611 |
| | Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy | Q37192616 |
| | Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword? | Q37603072 |
| | Defective autophagy control by the p53 rheostat in cancer | Q37659681 |
| | Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence? | Q42643410 |
| | Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells | Q42666630 |
| | Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice | Q42742417 |
| | P3Kα: a driver of tumor metastasis? | Q42751622 |
| | mTOR pathway activation in age-related retinal disease | Q42762402 |
| | Metabolism meets autophagy | Q42780796 |
| | Phosphorylation of AKT: a mutational analysis | Q42827667 |
| | Shifting senescence into quiescence by turning up p53 | Q42845576 |
| | Vitamin D: a new player in the world of mTOR signaling | Q42862925 |
| | Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression | Q42863180 |
| | mTOR goes to the nucleus. | Q42936243 |
| | A feedback loop between mTOR and tRNA expression? | Q42940121 |
| | How does the mammalian target of rapamycin (mTOR) influence CD8 T cell differentiation? | Q42941155 |
| | Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation? | Q42941158 |
| | Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia.. | Q43041958 |
| | Regulation of cell migration by mTOR is mediated through changes in p27Kip1 phosphorylation | Q43053534 |
| | Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells | Q43082934 |
| | Exploiting the mTOR paradox for disease prevention | Q43082956 |
| | mTOR signaling in the control of activation of primordial follicles. | Q43092935 |
| | Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells | Q43122718 |
| | mTOR protein localization is cell cycle-regulated. | Q53210684 |
| | Coordinated epigenetic regulation of autophagy and apoptosis. | Q53223550 |
| | Inflammation and autophagy conspire to promote tumor growth. | Q53226852 |
| | Tuberin and mTOR, a key apoptotic pathway in diabetes. | Q53240635 |
| | Multiple pathways counteract cell death induced by RB1 loss: implications for cancer. | Q53250463 |
| | Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells. | Q53266494 |
| | Starved cells use mitochondria for autophagosome biogenesis | Q53299797 |
| | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies | Q39383689 |
| | Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. | Q39389293 |
| | The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. | Q39395115 |
| | Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes | Q39398353 |
| | Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer | Q39411477 |
| | Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors | Q39424181 |
| | Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression | Q39430569 |
| | Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. | Q39446680 |
| | AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. | Q39463725 |
| | Wnt and Kras signaling-dark siblings in lung cancer | Q39507181 |
| | Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias. | Q39507930 |
| | Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. | Q39528447 |
| | COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. | Q39575398 |
| | Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. | Q39590044 |
| | In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. | Q39602151 |
| | Phospho-ΔNp63α/Rpn13-dependent regulation of LKB1 degradation modulates autophagy in cancer cells | Q39614537 |
| | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. | Q39630008 |
| | p21Waf1is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate | Q39646025 |
| | Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status | Q39648560 |
| | Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 |
| | Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage | Q39663338 |
| | FM19G11: A new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways | Q39672963 |
| | Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors | Q39690774 |
| | Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. | Q39746181 |
| | mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes | Q39758212 |
| | Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells | Q39761225 |
| | Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism | Q39848311 |
| | mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter | Q39859853 |
| | Eph receptor and mTOR pathway crosstalk: implications for cancer | Q41784769 |
| | mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging | Q41809553 |
| | The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway | Q41841005 |
| | The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway | Q41861305 |
| | Mitochondrial dysfunction and cell senescence--skin deep into mammalian aging | Q41933958 |
| | Another "Janus paradox" of p53: induction of cell senescence versus quiescence | Q41949647 |
| | Adult-onset, short-term dietary restriction reduces cell senescence in mice. | Q42017882 |
| | TP53 and MTOR crosstalk to regulate cellular senescence | Q42356990 |
| | Decision-making by p53 and mTOR. | Q42549708 |
| | Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis | Q35159014 |
| | AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers | Q35169608 |
| | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells | Q35556981 |
| | Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling | Q35590438 |
| | Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence | Q35640152 |
| | Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma | Q35640196 |
| | Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | Q35640228 |
| | Elevated PI3K signaling drives multiple breast cancer subtypes | Q35640263 |
| | The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer | Q35640296 |
| | Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells | Q35640301 |
| | Hormesis does not make sense except in the light of TOR-driven aging | Q35645142 |
| | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 |
| | Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity | Q35679369 |
| | Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture | Q35679387 |
| | Molecular damage in cancer: an argument for mTOR-driven aging | Q35740772 |
| | Recent progress in targeting cancer | Q35740782 |
| | Conserved role of medium acidification in chronological senescence of yeast and mammalian cells | Q35747488 |
| | PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells | Q35764344 |
| | Targeting autophagy addiction in cancer | Q35764384 |
| | Will PI3K pathway inhibitors be effective as single agents in patients with cancer? | Q35764392 |
| | Metformin: multi-faceted protection against cancer | Q35764409 |
| | CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms | Q35828815 |
| | Automated image analysis of nuclear shape: what can we learn from a prematurely aged cell? | Q35857196 |
| | Novel targeted therapies for mantle cell lymphoma | Q35889841 |
| | Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging | Q35947377 |
| | Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. | Q35947388 |
| | Rapamycin increases oxidative stress response gene expression in adult stem cells | Q36021893 |
| | Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts | Q36050677 |
| | Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation | Q36050683 |
| | Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. | Q36062176 |
| | Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? | Q36209128 |
| | Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels | Q36339232 |
| | Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice | Q36455201 |
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| | signal transduction | Q828130 |
| | neoplasm | Q1216998 |
| | antineoplastic | Q2853144 |
| | protein kinase inhibitors | Q7251487 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1505-21 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Advances in targeting signal transduction pathways | |
| P478 | volume | 3 | |